Literature DB >> 22651115

Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes.

Peter F Thall1, Hoang Q Nguyen.   

Abstract

A sequentially outcome-adaptive Bayesian design is proposed for choosing the dose of an experimental therapy based on elicited utilities of a bivariate ordinal (toxicity, efficacy) outcome. Subject to posterior acceptability criteria to control the risk of severe toxicity and exclude unpromising doses, patients are randomized adaptively among the doses having posterior mean utilities near the maximum. The utility increment used to define near-optimality is nonincreasing with sample size. The adaptive randomization uses each dose's posterior probability of a set of good outcomes, defined by a lower utility cutoff. Saturated parametric models are assumed for the marginal dose-toxicity and dose-efficacy distributions, allowing the possible requirement of monotonicity in dose, and a copula is used to obtain a joint distribution. Prior means are computed by simulation using elicited outcome probabilities, and prior variances are calibrated to control prior effective sample size and obtain a design with good operating characteristics. The method is illustrated by a Phase I/II trial of radiation therapy for children with brainstem gliomas.

Entities:  

Mesh:

Year:  2012        PMID: 22651115      PMCID: PMC3385658          DOI: 10.1080/10543406.2012.676586

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  15 in total

1.  Dose-finding designs for HIV studies.

Authors:  J O'Quigley; M D Hughes; T Fenton
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Bayesian optimal designs for Phase I clinical trials.

Authors:  Linda M Haines; Inna Perevozskaya; William F Rosenberger
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

3.  An adaptive dose-finding design incorporating both toxicity and efficacy.

Authors:  Wei Zhang; Daniel J Sargent; Sumithra Mandrekar
Journal:  Stat Med       Date:  2006-07-30       Impact factor: 2.373

4.  Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.

Authors:  Emily M Van Meter; Elizabeth Garrett-Mayer; Dipankar Bandyopadhyay
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

5.  A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.

Authors:  B Nebiyou Bekele; Yu Shen
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

6.  Dose-finding based on efficacy-toxicity trade-offs.

Authors:  Peter F Thall; John D Cook
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

7.  Patient-specific dose finding based on bivariate outcomes and covariates.

Authors:  Peter F Thall; Hoang Q Nguyen; Elihu H Estey
Journal:  Biometrics       Date:  2008-03-19       Impact factor: 2.571

8.  The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes.

Authors:  Thomas M Braun
Journal:  Control Clin Trials       Date:  2002-06

9.  Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.

Authors:  Nadine Houede; Peter F Thall; Hoang Nguyen; Xavier Paoletti; Andrew Kramar
Journal:  Biometrics       Date:  2009-08-10       Impact factor: 2.571

10.  The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

Authors:  Z Yuan; R Chappell; H Bailey
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

View more
  27 in total

1.  Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome.

Authors:  Peter F Thall; Hoang Q Nguyen; Sarah Zohar; Pierre Maton
Journal:  J Am Stat Assoc       Date:  2014-09-01       Impact factor: 5.033

2.  A decision-theoretic phase I-II design for ordinal outcomes in two cycles.

Authors:  Juhee Lee; Peter F Thall; Yuan Ji; Peter Müller
Journal:  Biostatistics       Date:  2015-11-09       Impact factor: 5.899

3.  Flexible Phase I-II design for partially ordered regimens with application to therapeutic cancer vaccines.

Authors:  Nolan A Wages; Craig L Slingluff
Journal:  Stat Biosci       Date:  2019-06-04

4.  A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling.

Authors:  Yanxun Xu; Peter F Thall; Peter Müller; Reza J Mehran
Journal:  Bayesian Anal       Date:  2016-07-26       Impact factor: 3.728

5.  Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.

Authors:  Nolan A Wages; Craig A Portell; Michael E Williams; Mark R Conaway; Gina R Petroni
Journal:  Clin Cancer Res       Date:  2017-07-21       Impact factor: 12.531

6.  Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.

Authors:  N A Wages; C L Slingluff; G R Petroni
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

7.  A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III.

Authors:  Andrew G Chapple; Peter F Thall
Journal:  Biometrics       Date:  2019-04-03       Impact factor: 2.571

8.  A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.

Authors:  Nolan A Wages; Craig L Slingluff; Gina R Petroni
Journal:  Contemp Clin Trials       Date:  2015-01-29       Impact factor: 2.226

9.  Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer.

Authors:  Thomas A Murray; Peter F Thall; Ying Yuan; Sarah McAvoy; Daniel R Gomez
Journal:  J Am Stat Assoc       Date:  2017-05-03       Impact factor: 5.033

10.  AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.

Authors:  Jiaying Lyu; Yuan Ji; Naiqing Zhao; Daniel V T Catenacci
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-06-13       Impact factor: 1.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.